Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT01970475 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01970475
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01970475 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Phase 3 Study of ABP 501 Efficacy and Safety Compared to Adalimumab in Subjects With Moderate to Severe Rheumatoid Arthritis
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
November 30, 2014
Enrollment
526 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid